- Home
- NPCE vs SLN Comparison
NPCE vs SLN Comparison
Compare NPCE & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCE
- SLN
- Stock Information
- Founded
- NPCE 1997
- SLN 1994
- Country
- NPCE United States
- SLN United Kingdom
- Employees
- NPCE N/A
- SLN N/A
- Industry
- NPCE Medical Specialities
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- NPCE Health Care
- SLN Health Care
- Exchange
- NPCE Nasdaq
- SLN Nasdaq
- Market Cap
- NPCE 292.9M
- SLN 299.4M
- IPO Year
- NPCE 2021
- SLN N/A
- Fundamental
- Price
- NPCE $9.15
- SLN $4.81
- Analyst Decision
- NPCE Strong Buy
- SLN Buy
- Analyst Count
- NPCE 6
- SLN 5
- Target Price
- NPCE $16.67
- SLN $32.60
- AVG Volume (30 Days)
- NPCE 205.3K
- SLN 61.8K
- Earning Date
- NPCE 08-12-2025
- SLN 08-07-2025
- Dividend Yield
- NPCE N/A
- SLN N/A
- EPS Growth
- NPCE N/A
- SLN N/A
- EPS
- NPCE N/A
- SLN N/A
- Revenue
- NPCE $88,570,000.00
- SLN $27,169,000.00
- Revenue This Year
- NPCE $22.13
- SLN N/A
- Revenue Next Year
- NPCE $6.07
- SLN N/A
- P/E Ratio
- NPCE N/A
- SLN N/A
- Revenue Growth
- NPCE 23.32
- SLN 22.28
- 52 Week Low
- NPCE $5.45
- SLN $1.97
- 52 Week High
- NPCE $18.98
- SLN $20.48
- Technical
- Relative Strength Index (RSI)
- NPCE 51.74
- SLN 34.88
- Support Level
- NPCE $8.61
- SLN $4.91
- Resistance Level
- NPCE $8.99
- SLN $5.34
- Average True Range (ATR)
- NPCE 0.53
- SLN 0.48
- MACD
- NPCE 0.11
- SLN -0.05
- Stochastic Oscillator
- NPCE 75.00
- SLN 0.71
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.